Open access
Oct 2026
Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1-mutated ER+/HER2- advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor.
CLINICAL TRIAL REGISTRATION www.clinicaltrials.gov identifier is NCT06382948; EU Clinical Trials identifier is EUCT 2024-512926-27-00.
J. Pérez-García, A. Llombart-Cussac, E. López-Miranda et al.
· Future Oncology · 0 citations